A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
Phase 3
Active, not recruiting
- Conditions
- Obesity
- Registration Number
- NCT06131437
- Lead Sponsor
- Novo Nordisk A/S
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- 800
Inclusion Criteria
Inclusion Criteria:<br><br> - Male or female<br><br> - Age 18 years or above at the time of signing the informed consent<br><br> - Body mass index (BMI) of = 30.0 kilogram per square meter (kg/m^2)<br><br>Exclusion Criteria:<br><br> - Glycated haemoglobin (HbA1c) = 6.5 % (48 millimoles per mole [mmol/mol]) as measured<br> by the central laboratory at screening<br><br> - History of type 1 or type 2 diabetes mellitus
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Relative change in body weight
- Secondary Outcome Measures
Name Time Method Achievement of greater than or equal to (=) 25% weight reduction;Achievement of = 30% weight reduction;Change in waist circumference;Change in systolic blood pressure (SBP);Change in diastolic blood pressure (DBP);Relative change in lipids: Total cholesterol;Relative change in lipids: High-density lipoprotein (HDL) cholesterol;Relative change in lipids: Non-HDL cholesterol;Relative change in lipids: Low-density lipoprotein (LDL) cholesterol;Relative change in lipids: Very low-density lipoprotein (VLDL) cholesterol;Relative change in lipids: Triglycerides;Number of Treatment-emergent Adverse Events (TEAEs);Number of Treatment Emergent Serious adverse events (TESAEs)